I think the company already had juice out . Last 5 yr profit grth and share price cagr huge difference between.

Anyone still tracking this counter

GSK PHARMA – Broad overview –

No 1 in India in – vaccines, anti-infectives derma therapies

Has 4 brands in top 50 branded generics in India. These are – Calpol (PCM), Augumentin (amoxycillin), T-Bact ( topical cream for bacterial skin infections ) and Ceftum ( Cefuroxime – a second Gen Cephalosporin ). Company launched brand extensions of two of these brands – Calpol 650+ and Augmentin ES in 2023. Eltroxin( for hyperthyroidism ), CCM ( Vit D supplement ), Neosporin ( topical cream for bacterial skin infections ), Betnovate ( anti-inflammatory skin cream ) are other popular brands from GSK

05 of GSK’s vaccines are ranked among top 15 vaccines brands in India. Have launched an adult vaccine in India to prevent – Shingles – in FY 23

In 2024, GSK will complete 100 yrs in India

Company also owns 02 popular speciality brands in India – Nucala ( only biologic treatment for eosinophilic asthma ) and Trelegy ( to treat obstructive pulmonary disease )

FY 23 financials –

Sales – 3216 vs 3218 cr

EBITDA – 800 vs 755 cr (margins @ 25 vs 23 pc)

PAT – 605 vs 552 cr

Current Size of IPM @ $52 billion. Expected to cross $ 100 billion by 2030

Company’s formulations facility is located at Maharashtra. Company has 22 Contract manufacturing partners in India

Disc: hold a tracking position, not SEBI registered, biased

ABBOTT INDIA – COMPANY OVERVIEW –

Key brands –

Udiliv ( chronic lever disease )

Influvac ( prevention of Influenza )

Pankreoflat ( indigestion )

Cremaffin ( constipation )

Arachitol ( Vit D deficiency )

Zolfresh ( Insomania )

Heptral ( liver disease )

Duphaston ( miscarriage, IVF )

Digene ( antacid )

Prothiaden ( depression )

Librax ( irritable bowel syndrome )

Brufen ( analgesic )

Duphalac ( constipation )

Thyronorm ( hypothyroidism )

Duvadilan ( pre-term labour )

Vertin ( vertigo )

New brand Launches –

Cremagel ( anal fissures )

Brufen P ( pain and fever )

Solfe ( anemia )

Total product portfolio of 125 products. 10 new products launched in FY 22-23

15 of company’s brands are ranked-1 in their respective categories and account for 80 pc of company’s revenues

Last 5 Yr CAGR –

Revenue – 9 pc

EBITDA – 16 pc

PAT – 17 pc

Book Value growth – 15 pc

Expanding aggressively into – Nepal, Bhutan, SriLanka and Maldives

Udiliv and Thyronorm are a part of top 15 India Pharma brands

With a strong portfolio of – Cremaffin, Duphalac, Cremaffin Plus – company commands a 38 pc mkt share in Laxative category

Therapy wise performance for FY 23 –

Women’s health –

Degrew by 8 pc due increased generic competition in Dydrogestrone mkt (company’s brand is Duphaston). This has been a pain point for the company for quite some time now. Launched a slew of new products to augment the women’s health portfolio – Femoston (post-menopausal symptoms), Solfe (anaemia) and Cetropro (IVF)

GI –

Grew @ healthy 11 pc. Cremaffin, Duphalac, Udiliv and Creon (pancreatic exocrine insufficiency) did very well. Librax and Ganaton (GI dismotility) continued their steady growth rates. New launches in the GI space included – Digeraft (gastroesophaegal reflux) and Cremagel

CNS –

Grew by 4 pc led by Vertin (to treat vertigo)

Metabolics –

Grew by a strong 15 pc led by Thyronorm. Also launched India’s first Liothyronine molecule – Linorma T-3 in FY 23. Combirorm (probiotics capsules) continues to gather momentum for treatment of bacterial vagenosis

Multi-Speciality –

Grew by 5 pc led by – Duvadilan, Zolfresh, Brufen. Aim to grow these into mega brands for the company. Brufen-P was launched this yr

Vaccines –

Grew by 6 pc led by – Influvac, Rotassure, Enteroshield (typhoid) and Havshield (Hepatitis A)

Future growth drivers –

Accelerate pillar brands
Multi-Channel doctor engagement
New launches to improve portfolio depth

Disc: hold a tracking position, not SEBI registered, biased

Thanks for the great level of details! Something to keep an eye on – huge amounts stuck in investories and receivables. To some extent important for a fast growing company, yet, conversion needs to be tracked?